Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 15, 2023

Primary Completion Date

June 15, 2024

Study Completion Date

November 15, 2024

Conditions

Interstitial Lung Disease Due to Systemic Disease (Disorder)

Interventions

DRUG

Upadacitinib 15 MG

oral tablet upadacitinib

DEVICE

Cellcept Oral Product

active control group 2000mg MMF daily

Trial Locations (1)

Medicinr, Asyut

All Listed Sponsors

lead

Assiut University

OTHER